Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 3/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.38 |
| ▸ | ALB | P02768 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.38 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8660992 | 0.91 | PDE3A (0.42) | PDE3APDE4DSLC29A1LMNATHRB | |
| SCHEMBL2580879 | 0.90 | PDE3A (0.41) | PDE3APDE4DSLC29A1LMNATHRB | |
| SCHEMBL1962181 | 0.88 | PDE3A (0.45) | PDE3APDE4DSLC29A1LMNATHRB | |
| SCHEMBL7775023 | 0.87 | PDE3A (0.44) | PDE3APDE4DSLC29A1LMNATHRB | |
| SCHEMBL4971926 | 0.86 | PDE3A (0.46) | PDE3APDE4DSLC29A1LMNATHRB | |
| SCHEMBL6408356 | 0.83 | PDE3A (0.43) | PDE3APDE4DSLC29A1LMNATHRB | |
| SCHEMBL28805006 | 0.82 | PDE3A (0.43) | PDE3APDE4DSLC29A1LMNATHRB | |
| SCHEMBL16245248 | 0.81 | PDE3A (0.45) | PDE3APDE4DSLC29A1LMNATHRB | |
| SCHEMBL31342963 | 0.81 | PDE3A (0.45) | PDE3APDE4DSLC29A1LMNATHRB | |
| SCHEMBL7517670 | 0.81 | PDE3A (0.43) | PDE3APDE4DSLC29A1LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1032405-A4 | ANTIMUTAGENIC COMPOSITIONS FOR TREATMENT AND PREVENTION OF PHOTODAMAGE TO SKIN | WELLSTAT THERAPEUTICS CORP (US) | 2007-05-02 | — | — | EP | claimed |
| US-RE39573-E1 | Antimutagenic compositions for treatment and prevention of photodamage to skin | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-04-17 | — | — | US | claimed |
| US-6465440-B2 | ADMINISTERING TO SKIN A COMPOSITION CONTAINING DEOXYRIBONUCLEOSIDES IN CONCENTRATIONS SUFFICIENT TO ENHANCE DNA REPAIR OR REDUCE MUTATION FREQUENCY IN A VEHICLE CAPABLE OF DELIVERING DEOXYRIBONUCLEOSIDES TO SKIN CELLS | WELLSTAT THERAPEUTICS CORPORATION | 2002-10-15 | — | — | US | claimed |
| US-6417170-B2 | ADMINISTERING TO SKIN A COMPOSITION CONTAINING DEOXYRIBONUCLEOSIDES IN CONCENTRATIONS SUFFICIENT TO ENHANCE DNA REPAIR OR REDUCE MUTATION FREQUENCY IN A VEHICLE CAPABLE OF DELIVERING DEOXYRIBONUCLEOSIDES TO SKIN CELLS | PRO-NEURON, INC. | 2002-07-09 | — | — | US | claimed |
| US-20020006913-A1 | ANTIMUTAGENIC COMPOSITIONS FOR TREATMENT AND PREVENTION OF PHOTODAMAGE TO SKIN | PRO-NEURON, INC. | 2002-01-17 | — | — | US | claimed |
| US-20010044421-A1 | Administering to skin a composition containing deoxyribonucleosides in concentrations sufficient to enhance DNA repair or reduce mutation frequency in a vehicle capable of delivering deoxyribonucleosides to skin cells | PRO-NEURON, INC. | 2001-11-22 | — | — | US | claimed |
| US-20010044419-A1 | Antimutagenic compositions for treatment and prevention of photodamage to skin | PRO-NEURON, INC. | 2001-11-22 | — | — | US | claimed |
| EP-1032405-A1 | ANTIMUTAGENIC COMPOSITIONS FOR TREATMENT AND PREVENTION OF PHOTODAMAGE TO SKIN | PRO-NEURON, INC. (US) | 2000-09-06 | — | — | EP | claimed |
| WO-1999022741-A1 | ANTIMUTAGENIC COMPOSITIONS FOR TREATMENT AND PREVENTION OF PHOTODAMAGE TO SKIN | PRO-NEURON, INC. (US) | 1999-05-14 | — | — | WO | claimed |
| US-11584772-B2 | N4-modified cytidine nucleotides and their use | VILNIUS UNIVERSITY (LT) | 2023-02-21 | — | — | US | disclosed |
| US-20200270295-A1 | N4-MODIFIED CYTIDINE NUCLEOTIDES AND THEIR USE | VILNIUS UNIVERSITY (LT) | 2020-08-27 | — | — | US | disclosed |
| EP-3681897-A1 | N4-MODIFIED CYTIDINE NUCLEOTIDES AND THEIR USE | Vilnius University (LT) | 2020-07-22 | — | — | EP | disclosed |
| WO-2019053609-A1 | N4-MODIFIED CYTIDINE NUCLEOTIDES AND THEIR USE | VILNIUS UNIVERSITY (LT) | 2019-03-21 | — | — | WO | disclosed |
| CN-107207555-A | Precipitation accelerator and precipitation method using the same | 味之素株式会社 | 2017-09-26 | — | — | CN | disclosed |
| US-20040192635-A1 | Acyl deoxyribonucleoside derivatives and uses thereof | WELLSTAT THERAPEUTICS CORPORATION (US) | 2004-09-30 | — | — | US | disclosed |
| US-6743782-B1 | ACYL DERIVATIVE OF 2'-DEOXYADENOSINE; TREATING OR PREVENTING RADIATION, MUTAGEN AND SUNLIGHT-INDUCED CELLULAR DAMAGE, IMPROVING WOUND HEALING AND TISSUE REPAIR, AMELIORATING THE EFFECTS OF AGING; ENHANCE BIOAVAILABILITY | WELLSTAT THERAPEUTICS CORPORATION | 2004-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584772-B2 | N4-modified cytidine nucleotides and their use | PNP, RNGTT, ADA | PDE3A 2081/4885PDE4D 717/4885SLC29A1 232/4885 |
| US-20200270295-A1 | N4-MODIFIED CYTIDINE NUCLEOTIDES AND THEIR USE | PNP, RNGTT, ADA | PDE3A 2081/4885PDE4D 717/4885SLC29A1 232/4885 |
| US-20040192635-A1 | Acyl deoxyribonucleoside derivatives and uses thereof | UNG, OGG1, NQO1 | PDE3A 1579/4885PDE4D 552/4885SLC29A1 2237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.